BENITEC BIOPHARMA INC
BNTCNASDAQπ #3198 by market capEarnings Feb 10US Equity
$7.94βΌ $0.21 (β2.52%)
Market closed Β· at closeTrack BNTC
Get earnings, price moves & breaking news on Telegram
24hβΌ 2.5%
7dβΌ 11.9%
14dβΌ 16.8%
30dβΌ 7.9%
ytdβΌ 41.2%
1yβΌ 40.1%
π¦Market Cap
$277M
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
100.0%
High
π΅FCF Margin
β
βοΈP/S Ratio
4084.0x
Expensive
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $7.82 β $7.99
- 52-Week Range
- $7.72 β $14.39
- Volume (shares)
- 3,499
- Avg Volume (shares)
- β
- Shares Outstanding
- 34.9M
- Next Earnings
- 2027-02-10
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 4084.0x
- EPS (TTM)
- $-1.11
- Dividend Yield
- β
- Dilution (1yr)
- +7.7%
BENITEC BIOPHARMA INC
BNTCFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β² +14.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$51Mβ² +22.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$17MβΌ β29.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
49.5Mβ² +7.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$176MβΌ β$12M YoY
About BENITEC BIOPHARMA INC
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
14 analysts
Strong Buy5
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.